Groowe Groowe / Newsroom / VNDA
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

VNDA News

Vanda Pharmaceuticals Inc.

Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight

globenewswire.com
IONS ALNY NVS BIIB ARWR SLN WVE VNDA NSP TCRT AMX CDIO SRPT VIR BNTX ARCT GSK PFE

Form 8-K

sec.gov
VNDA

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

prnewswire.com
VNDA

Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight

globenewswire.com
VNDA GRFS BHC RDHL MRK TEVA PFE SNY LLY ABBV AZN CRCT SPRO CRNX

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

prnewswire.com
VNDA

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

prnewswire.com
VNDA

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

prnewswire.com
VNDA ANAB

Vendavo Named a Leader in the Gartner® Magic Quadrant™ for B2B Pricing & Rebate Optimization Software

prnewswire.com
VNDA

Form 8-K

sec.gov
VNDA

Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors

prnewswire.com
VNDA